Українська Abstract
Given the increasing prevalence of cardiovascular diseases and their complications, the study of effective approaches to lipid-lowering therapy, especially in patients with comorbid conditions, is a highly relevant task in modern cardiology. The aim of this study was to analyse modern therapeutic strategies for lowering low-density lipoprotein cholesterol (LDL-C) in patients with chronic heart failure (CHF) due to ischaemic heart disease (IHD), with concomitant obesity and type 2 diabetes mellitus. We also evaluated their effectiveness and safety, taking into account the latest clinical data. The study included 225 patients with ischaemic CHF, who were divided into four groups according to the presence of metabolic disorders. The effectiveness of lipid-lowering therapy with rosuvastatin (20-40 mg) and ezetimibe was assessed. Rosuvastatin monotherapy at a dose of 20 mg enabled only partial achievement of target LDL-C levels (< 1.4 mmol/L): these were reached by 44% of patients in the first group, 56% in the second, 58% in the third, and 66% in the fourth. Some patients independently discontinued the medication. Further escalation of therapy (increasing the dose of rosuvastatin or adding ezetimibe) significantly improved lipid profile parameters. Combined therapy with rosuvastatin 20 mg and ezetimibe 10 mg proved to be highly effective in patients at extreme risk, allowing them to achieve target LDL-C levels (< 1.0 mmol/L) in 95.5% of cases. Achieving target low-density lipoprotein cholesterol levels in patients with chronic heart failure and ischaemic heart disease, especially in the presence of concomitant type 2 diabetes mellitus and obesity, is a complex task. Statin monotherapy is often insufficiently effective, which requires the use of combined hypolipidaemic therapy. The value of this work lies in confirming the need for an individualised approach to the treatment of dyslipidaemia and the importance of increasing patient adherence to the prescribed therapy to achieve optimal results
Keywords:
[1] Nakamura K, Miyoshi T, Yoshida M, Akagi S, Saito Y, Ejiri K, et al. Pathophysiology and treatment of diabetic cardiomyopathy and heart failure in patients with diabetes mellitus. Int J Mol Sci. 2022;23(7):3587. DOI: 10.3390/ ijms23073587
[2] Jankauskas SS, Kansakar U, Varzideh F, Wilson S, Mone P, Lombardi A, et al. Heart failure in diabetes. Metabolism. 2021;125:154910. DOI: 10.1016/j.metabol.2021.154910
[3] Mhaimeed O, Burney ZA, Schott SL, Kohli P, Marvel FA, Martin SS. The importance of LDL-C lowering in atherosclerotic cardiovascular disease prevention: Lower for longer is better. Am J Prev Cardiol. 2024;18:100649. DOI: 10.1016/j.ajpc.2024.100649
[4] Da Dalt L, Cabodevilla AG, Goldberg IJ, Norata GD. Cardiac lipid metabolism, mitochondrial function, and heart failure. Cardiovasc Res. 2023;119(10):1905–14. DOI: 10.1093/cvr/cvad100
[5] Yu J, Zhou G, Guo Y, Long Y. Inflammation in heart failure: Mechanisms and therapeutic strategies. CVIA. 2025;10(1). DOI: 10.15212/CVIA.2024.0050
[6] Raschi E, Casula M, Cicero AFG, Corsini A, Borghi C, Catapano A. Beyond statins: New pharmacological targets to decrease LDL-cholesterol and cardiovascular events. Pharmacol Ther. 2023;250:108507. DOI: 10.1016/j. pharmthera.2023.108507
[7] Mak YH, Chua F, Koh XH, Tan VH, Lee ZH, Lam A, et al. Low-density lipoprotein cholesterol goal attainment and mortality in ischaemic heart disease: A two-year observational study. Singapore Med J. 2025;66(3):154–62. DOI: 10.4103/singaporemedj.SMJ-2024-172
[8] Wróbel-Nowicka K, Wojciechowska C, Jacheć W, Zalewska M, Romuk E. The role of oxidative stress and inflammatory parameters in heart failure. Medicina (Kaunas). 2024;60(5):760. DOI: 10.3390/medicina60050760
[9] Shved M, Yastremska I, Levytska L, Kuchmiy V, Prokopovych O, Kitsak Y, Liakhovych R. Clinical portrait of a patient with acute coronary syndrome and type 2 diabetes mellitus: A novel strategy for the diagnosis, prognosis and treatment. Int J Endocrinol. 2024;20(7):504–10. DOI: 10.22141/2224-0721.20.7.2024.1449
[10] Koval OA, Romanenko SV, Kaplan PO, Pugach TV. Effectiveness and tolerability of early initiation of combined lipid-lowering therapy included simvastatin and fenofibrate vs simvastatin alone in patients with acute coronary syndrome and type 2 diabetes mellitus with hypertriglyceridemia. UJC. 2020;27(2):34–45. DOI: 10.31928/1608635X-2020.2.3445
[11] 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies With the special contribution of the European Association of Preventive Cardiology (EAPC). Europ Heart J. 2022;43(42):4468. DOI: 10.1093/eurheartj/ehac458
[12] Iannuzzo G, Kamboj G, Barman P, Dongare S, Jawla S. Efficacy and safety of lipid-lowering therapies in combination with or without statin to reduce the cardiovascular risk: A systematic review of randomised controlled trials. Atheroscler Plus. 2024;58:24–37. DOI: 10.1016/j.athplu.2024.10.001
[13] American Diabetes Association. Standards of medical care in diabetes – 2019 abridged for primary care providers. Clin Diabetes. 2019;37(1):11–34. DOI: 10.2337/cd18-0105
[14] International Diabetes Federation. 2018 UN High Level Meeting On NCDs IDF diabetes advocacy toolkit. Brussels: International Diabetes Federation; 2018. 34 P.
[15] Vrints C, Andreotti F, Koskinas KC, Rossello X, Adamo M, Ainslie J, et al. 2024 ESC Guidelines for the management of chronic coronary syndromes: Developed by the task force for the management of chronic coronary syndromes of the European Society of Cardiology (ESC) Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024;45(36):3415–537. DOI: 10.1093/eurheartj/ehae177
[16] Unified clinical protocol of primary, secondary (specialised) and tertiary (highly specialized) medical care “Stable Ischemic Heart Disease” [Internet]. 2021 [cited 2025 April 5]. Available from: https://www.dec.gov.ua/wp-content/ uploads/2021/12/2021_2857_ykpmd_stabihs.pdf
[17] Order of the Ministry of Health of Ukraine No. 2857. On Approval of the Unified Clinical Protocol for Primary, Secondary (Specialised) and Tertiary (Highly Specialised) Medical Care “Stable Ischemic Heart Disease” [Internet]. 2021 December 23 [cited 2025 April 5]. Available from: https://www.dec.gov.ua/wp-content/uploads/2021/12/2021_2857_ nakaz_stabihs.pdf
[18] Voronkov LH, Berezin OE, Zharinov OY, Zhebel VM, Ivaniv YA, Karpenko YU, et al. Recommendations for the diagnosis and classification of chronic heart failure. Kyiv: Ukrainian Association of Cardiology; 2024. 72 P.
[19] Criteria Committee of the New York Heart Association. Nomenclature and criteria for diagnosis of diseases of the heart and great vessels. 9th ed. Boston (MA): Little, Brown & Co; 1994. 334 P.
[20] Order of the Ministry of Health of Ukraine No. 1300. Unified Clinical Protocol for Primary and Specialized Medical Care: Type 2 Diabetes in Adults [Internet]. 2024 July 24 [cited 2025 April 5]. Available from: https://www.dec.gov.ua/ mtd/czukrovyj-diabet-2-typu/
[21] World Medical Association. WMA Declaration of Helsinki: Ethical principles for medical research involving human participants [Internet]. 2024 [cited 2025 April 5]. Available from: https://www.wma.net/policies-post/wmadeclaration-of-helsinki/
[22] UNESCO. Universal declaration on bioethics and human rights [Internet]. 2006 [cited 2025 April 5]. Available from: https://unesdoc.unesco.org/ark:/48223/pf0000146180_ukr
[23] Patel SB, Wyne KL, Afreen S, Belalcazar LM, Bird MD, Coles S, et al. American Association of Clinical Endocrinology clinical practice guideline on pharmacologic management of adults with dyslipidemia. Endocr Pract. 2025;31(2):236– 62. DOI: 10.1016/j.eprac.2024.09.016
[24] Morrison AM, Sullivan AE, Aday AW. Atherosclerotic disease: Pathogenesis and approaches to management. Med Clin North Am. 2023;107(5):793–805. DOI:10.1016/j.mcna.2023.04.004
[25] Gu J, Sanchez RJ, Chauhan A, Fazio S, Rosenson RS. Simulation of lipid-lowering therapy (LLT) intensification in very high-risk patients with atherosclerotic cardiovascular disease. J Clin Lipidol. 2022;16(6):901–5. DOI:10.1016/j. jacl.2022.10.001
[26] Danielson E, Melin-Johansson C, Modanloo M. Adherence to treatment in patients with chronic diseases: From alertness to persistence. Int J Community Based Nurs Midwifery. 2019;7(4):248–57. DOI: 10.30476/IJCBNM.2019.81303.0
[27] Berardinelli D, Conti A, Hasnaoui A, Casabona E, Martin B, Campagna S, et al. Nurse-led interventions for improving medication adherence in chronic diseases: A systematic review. Healthcare (Basel). 2024;12(23):2337. DOI: 10.3390/ healthcare12232337
[28] Ah YM, Jeong M, Choi HD. Comparative safety and efficacy of low- or moderate-intensity statin plus ezetimibe combination therapy and high-intensity statin monotherapy: A meta-analysis of randomized controlled studies. PLoS One. 2022;17(3):e0264437. DOI: 10.1371/journal.pone.0264437
[29] Orel M, Martynyuk L. Correction of endothelial dysfunction in patients with hypertension, dyslipidaemia, and decreased thyroid function. IJMMR. 2023;9(1):24–31. DOI: 10.61751/ijmmr.2413-6077.2023.1.24
[30] Leosdottir M, Schubert J, Brandts J, Gustafsson S, Cars T, Sundström J, et al. Early ezetimibe initiation after myocardial infarction protects against later cardiovascular outcomes in the SWEDEHEART registry. J Am Coll Cardiol. 2025;85(15):1550–64. DOI: 10.1016/j.jacc.2025.02.007